Immunovant
IMVT
About: Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Employees: 362
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 48
14% more call options, than puts
Call options by funds: $6.75M | Put options by funds: $5.95M
0.89% more ownership
Funds ownership: 55.41% [Q1] → 56.3% (+0.89%) [Q2]
4% less capital invested
Capital invested by funds: $1.61B [Q1] → $1.54B (-$68.9M) [Q2]
13% less funds holding
Funds holding: 192 [Q1] → 168 (-24) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q1] → 4 (-2) [Q2]
48% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 48
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
HC Wainwright & Co.
Douglas Tsao
|
$35
|
Buy
Reiterated
|
4 Sep 2025 |
|
JP Morgan
Brian Cheng
|
$37
|
Overweight
Maintained
|
12 Aug 2025 |
|
B of A Securities
Jason Gerberry
|
$30
|
Buy
Maintained
|
12 Aug 2025 |
|
UBS
Ashwani Verma
|
$18
|
Neutral
Maintained
|
28 Jul 2025 |
Financial journalist opinion
Based on 5 articles about IMVT published over the past 30 days
